Evidence map›Paper›PMID 35138150›Full record

ArticleMicrobiology spectrum2022

Impact of Empirical Antibiotic Therapy on Outcomes of Outpatient Urinary Tract Infection Due to Nonsusceptible

Michael W Dunne, Sailaja Puttagunta, Steven I Aronin, Stephen Brossette, John Murray, Vikas Gupta

Open access · goldAbstract read
In one paragraph

Article in Microbiology spectrum, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
7.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 48 citations in OpenAlex.

  1. Trial
  2. Sulopenem or Ciprofloxacin for the Treatment of Uncomplicated Urinary Tract Infections in Women: A Phase 3, Randomized Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023
    Trial
  3. Article
  4. Review
  5. Article
  6. Article
  7. Recurrent Urinary Tract Infection Caused by Multidrug-ResistantCase reports in infectious diseases · 2026
    Article
  8. Article
  9. Article
  10. CAUTIon - not all UTIs are the same.Nature reviews. Urology · 2025
    Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Observational
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Michael W DunneIterum Therapeutics, Old Saybrook, Connecticut, USA.
Sailaja PuttaguntaIterum Therapeutics, Old Saybrook, Connecticut, USA.
Steven I AroninIterum Therapeutics, Old Saybrook, Connecticut, USA.ORCID 0000-0002-4041-043X
Stephen BrossetteBecton, Dickinson and Company, Franklin Lakes, New Jersey, USA.
John MurrayBecton, Dickinson and Company, Franklin Lakes, New Jersey, USA.
Vikas GuptaBecton, Dickinson and Company, Franklin Lakes, New Jersey, USA.
Becton Dickinson (United States) · USFulcrum Therapeutics (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Resistance to oral antibiotics commonly used to treat outpatient urinary tract infections (UTIs) is increasing, but the implications of empirical treatment of resistant pathogens are not well described. Using an electronic records database, we reviewed the outcomes of patients >18 years of age who developed an outpatient UTI and had an outpatient urine culture result showing a member of the order

Indexed as

AdultAgedAnti-Bacterial AgentsEnterobacteriaceaeEnterobacteriaceae InfectionsFemaleHumansMaleMiddle AgedOutpatientsTreatment OutcomeUrinary Tract InfectionsAnti-Bacterial Agentsantimicrobial resistanceGram-negative bacteriaurinary tract infection

Identifiers

PMID35138150
PMCPMC8826825
OpenAlexW4210905127

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.